| Project/Area Number |
23590955
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Research Institute, International Medical Center of Japan |
|---|
Principal Investigator |
DOHI Taeko 独立行政法人国立国際医療研究センター, 研究所 肝炎・免疫研究センター 消化器疾患研究部, 部長 (60250221)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
KAWAMURA I Yuki 国立国際医療研究センター研究所肝炎・免疫研究センター, 消化器疾患研究部, 病態生理研究研究室長・室長 (10392391)
ISHIZAKA Yukihito 国立国際医療研究センター研究所, 副所長 (30281687)
|
|---|
| Research Collaborator |
OTSUBO Takeshi 国立国際医療研究センター研究所肝炎・免疫研究センター, 消化器疾患研究部, 特任研究員 (00623034)
KAWASHIMA Rei 北里大学, 医療衛生学部, 助教 (70392389)
BURKLY Linda C. Distinguished Investigator, Departments of Immunobiology and Drug Discovery, Biogen Idec
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 消化管上皮細胞 / TWEAK / Fn14 / DNA傷害 / 炎症 / 消化管炎症 / TNFSF / レトロトランスポジション / TNFSP |
|---|
| Research Abstract |
TNF-like weak inducer of apoptosis (TWEAK) is a member of TNF superfamily (TNFSF). Its receptor FGF-inducible molecule-14 (Fn14) has been identified. DNA damage is induced by gamma-irradiation and anti-cancer drugs. Gastrointestinal mucosal damage is one of the most significant side-effects of these treatments, which limits the dose of treatment. In this study, we found that TWEAK/Fn14 pathway is significantly involved in the DNA damage of intestinal mucosa that induced by gamma-irradiation and some type of anti-cancer drugs. Particularly, TWEAK enhances death signal mediated by Tumor necrosis factor (TNF)-alfa. results suggest the possible application of TWEAK inhibitors to prevent mucosal damage in cancer therapy.
|
